MDNAF (Medicenna Therapeutics) Ending Cash Position: $4.56 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDNAF Medicenna Therapeutics Corp MDNAF
29 GF Score
Price $0.29
! 1 Warning Sign
View Full Analysis

What is Medicenna Therapeutics Ending Cash Position?

Medicenna Therapeutics MDNAF +2.79% 29 Ending Cash Position is $4.56 Mil as of Mar. 2026. GuruFocus rates MDNAF with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

Medicenna Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was $4.56 Mil.

Medicenna Therapeutics's quarterly Ending Cash Position declined from Sep. 2025 ($11.38 Mil) to Dec. 2025 ($7.69 Mil) and declined from Dec. 2025 ($7.69 Mil) to Mar. 2026 ($4.56 Mil).

Medicenna Therapeutics's annual Ending Cash Position increased from Mar. 2024 ($12.55 Mil) to Mar. 2025 ($17.30 Mil) but then declined from Mar. 2025 ($17.30 Mil) to Mar. 2026 ($4.56 Mil).

Medicenna Therapeutics Ending Cash Position Related Terms

Medicenna Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Medicenna Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicenna Therapeutics Ending Cash Position Chart

Medicenna Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.22 24.55 12.55 17.30 4.56

Medicenna Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.30 14.97 11.38 7.69 4.56
MDNAF
29GF Score
Medicenna Therapeutics Corp MDNAF
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicenna Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Medicenna Therapeutics's Ending Cash Position for the fiscal year that ended in Mar. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=18.103+-13.547
=4.56

Medicenna Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=7.737+-3.181
=4.56

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $4.56 Mil mean?
Medicenna Therapeutics (MDNAF) has a Ending Cash Position of $4.56 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Medicenna Therapeutics and its competitors.
Is Medicenna Therapeutics' Ending Cash Position too high?
Medicenna Therapeutics' current Ending Cash Position is $4.56 Mil. Overall, Medicenna Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Medicenna Therapeutics' Ending Cash Position compare to VRTX and REGN?
Medicenna Therapeutics' Ending Cash Position of $4.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Medicenna Therapeutics and its competitors. Medicenna Therapeutics's current Ending Cash Position is $4.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicenna Therapeutics stock overvalued right now?
Medicenna Therapeutics (MDNAF) has a current Ending Cash Position of $4.56 Mil. The current Ending Cash Position is $4.56 Mil. Medicenna Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Medicenna Therapeutics (MDNAF), the current Ending Cash Position is $4.56 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medicenna Therapeutics Business Description

Other Exchanges MDNA:Canada
Address 2 Bloor Street West, Suite 903, Toronto, ON, CAN, M4W 3E2
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates include MDNA11 for Cancer immunotherapies, MDNA55 is a Molecular Trojan Horse, and BiSKITs represent a novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
29GF Score

Get the complete analysis for MDNAF

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.29
Price